DRKS00011220
招募中
不适用
Prospective observational study investigating Chemotherapies in untreated patients withnewly diagnosed primary CNS-Lymphoma (PCNSL) - NOA13
Knappschaftskrankenhaus Bochum-Langendreer0 个研究点目标入组 200 人2020年4月14日
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Primary CNS-Lymphoma
- 发起方
- Knappschaftskrankenhaus Bochum-Langendreer
- 入组人数
- 200
- 状态
- 招募中
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •PZNSL confirmed in histology, cytology or immunocytology
- •No Lymphoma manifestations outside the CNS
- •No contraindications for intensive chemo therapy
- •Consent to paticipation
排除标准
- •Lymphoma manifestations outside the CNS,
- •preceding or planned WBRT,
- •previous PCNSL therapy other than corticosteroids,
- •active uncontrolled infection,
- •immunosuppression, concomitant immunsuppressive therapy
- •status post organ Transplantation,
- •HIV infection,
- •concomitant malignancy in the last 5 years other than basal cell carcinoma or carcinoma in situ of the Cervix,
结局指标
主要结局
未指定
相似试验
招募中
不适用
Changing pattern and Impact factors of Prolonged FatigueSymptoms, signs and abnormal clinical and laboratory findings, NECKCT0001889Kyung Hee University Oriental Medicine Hospital at Gangdong200
已完成
不适用
changes in lung and kidney functions in patients undergoing robotic prostate surgeryHealth Condition 1: N428- Other specified disorders of prostateCTRI/2018/12/016755MAX SMART SUPER SPECIALITY HOSPITAL SAKET70
Enrolling By Invitation
不适用
Prospective observational study of the use of a cholesterol emulsion in Smith-Lemli-Opitz syndrome (SLO)Q87.1Congenital malformation syndromes predominantly associated with short statureDRKS00015064niversitätsklinikum Münster7
进行中（未招募）
1 期
Chemotherapy-free combination of PCI-32765 (Ibrutinib) with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and High Tumor BurdeStage II - IV follicular lymphoma grade 1 - 3a and a high tumor burden not previously treatedMedDRA version: 20.0Level: PTClassification code 10016908Term: Follicle centre lymphoma, follicular grade I, II, III stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016910Term: Follicle centre lymphoma, follicular grade I, II, III stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016909Term: Follicle centre lymphoma, follicular grade I, II, III stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2014-005164-15-DEKlinikum der Universität München, Medizinische Klinik und Poliklinik III
进行中（未招募）
1 期
Chemotherapy-free combination of Copanlisib withObinutuzumab (GA 101) in Patients with Previously Untreated FollicularLymphoma (FL) and High Tumor BurdeFollicular Lymphoma with high tumor burden (grade 1- 3a, Ann Arbour stage II - IV, previously untreated)MedDRA version: 21.1Level: PTClassification code 10016908Term: Follicle centre lymphoma, follicular grade I, II, III stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10016909Term: Follicle centre lymphoma, follicular grade I, II, III stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10016910Term: Follicle centre lymphoma, follicular grade I, II, III stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2018-004038-13-DEKlinikum der Universität München102